Washington University in St Louis - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Date: November 8, 2018
Pages: 63
Price:
US$ 250.00
License [?]:
Publisher: GlobalData
Report type: Company Report
Delivery: E-mail Delivery (PDF)
ID: W5451981DE4EN
Leaflet:

Download PDF Leaflet

Washington University in St Louis - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Summary

Washington University in St Louis (WUSTL), a subsidiary of University of Washington is an educational university which provides education and research services. The university provides various courses of bachelor’s, master’s, and doctoral degrees in a wide range of traditional and interdisciplinary fields. It provides degree programs in the areas of law, engineering, education, business and international affairs, medicine, public health, and others. The university’s schools include School of Engineering & Applied Science, Sam Fox School of Design and Visual Arts, George Warren Brown School of Social Work, and others. WUSTL is headquartered in St. Louis, Missouri, the US.

Washington University in St Louis - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope
  • Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
  • Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
  • Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
  • Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
  • Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
  • Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
  • Business Description - A brief description of the company's operations.
  • Key Employees - A list of the key executives of the company.
  • Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
  • Key Competitors - A list of the key competitors of the company.
  • Key Recent Developments - A brief on recent news about the company.
Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
  • The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
  • The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
  • Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
  • The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
  • Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
  • Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company.

NOTE: Out of security concerns GlobalData requires using corporate email address.
Washington University in St Louis, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
Washington University in St Louis, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018
Washington University in St Louis, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018
Washington University in St Louis, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018
Washington University in St Louis, Medical Devices Deals, 2012 to YTD 2018
Washington University in St Louis, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018
Washington University in St Louis, Pharmaceuticals & Healthcare, Deal Details
Partnerships
Pfizer Enters into Agreement with Washington University in St. Louis
GenVec Enters into Agreement with Washington University in St. Louis
MaxCyte Enters into Agreement with Washington University in St Louis
Turing Pharma Enters into Partnership with Washington University
Johnson & Johnson Innovation Enters into Research Agreement with Washington University
GenVec Enters into Agreement with Washington University at St. Louis
Licensing Agreements
Q BioMed to Expand Option Agreement with Washington University
Disarm Therapeutics Enters into Licensing Agreement with Washington University in St. Louis
Canopy Biosciences Enters into Licensing Agreement with Washington University in St. Louis and Johns Hopkins University
Precision Virologics Enters into Licensing Agreement with Washington University
Accuronix Therapeutics Enters into Licensing Agreement with Washington University in St. Louis
ViewPoint Therapeutics Receives Technology Rights from University of Michigan and Washington University
Sage Therapeutics Enters Into Licensing Agreement With Washington University To Develop Gaba Receptor Small Molecules
ChromaDex Amends Licensing Agreement With Washington University For Nicotinamide Riboside
Fimbrion Therapeutics Enters into Licensing Agreement with Washington University
Washington University in St Louis - Key Competitors
Washington University in St Louis - Key Employees
Washington University in St Louis - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Recent Developments
Government and Public Interest
Nov 01, 2018: Orion Research Foundation grants million euros for research in 2019
Oct 15, 2018: New child maltreatment research center launched with $6.5 million NIH grant
Oct 04, 2018: NIH funds specialized centers for child maltreatment research
Aug 02, 2018: Role of cell group behavior in cancer target of $1.9 million award
Jun 28, 2018: Kuehner commits $15 million to fund personalized medicine research
Jun 11, 2018: $14 million to fund research aimed at reducing childhood obesity
May 23, 2018: Foundation for Anesthesia Education and Research Awards $1.4 million in Grants
Apr 26, 2018: Noninvasive brain tumor biopsy on the horizon
Feb 27, 2018: Cure Alzheimer's Fund Issued more than $15 Million in Research Grants in 2017
Feb 27, 2018: Engineer develops enabling technology for emerging gene therapies
Nov 02, 2017: Lung Cancer Research Foundation Awards $1.6 Million in Research Grants
Oct 02, 2017: TSRI Researchers Join National Digital Health Informatics Collaborative
Sep 25, 2017: Human antibodies from dengue patients can effectively treat Zika infection in mice
Sep 25, 2017: Antibody protects against both Zika and dengue, mouse study shows
Sep 20, 2017: Newly ID’d role of major Alzheimer’s gene suggests possible therapeutic target
Jul 17, 2017: Top Cancer Research Facilities Nationwide Fueled With $1.2 Million In New Slate Of Grants
Apr 27, 2017: Stem cells edited to fight arthritis
Mar 13, 2017: University Of Utah Engineers Use CRISPR Technology To Prevent Tissue Damage And Resulting Chronic Pain
Clinical Trials
Oct 26, 2017: NIH study identifies new targets for anti-malaria drugs
Other Significant Developments
Sep 04, 2018: Focused delivery for brain cancers
Appendix
Methodology
About GlobalData
Contact Us
Disclaimer

LIST OF TABLES

Washington University in St Louis, Pharmaceuticals & Healthcare, Key Facts
Washington University in St Louis, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
Washington University in St Louis, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018
Washington University in St Louis, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018
Washington University in St Louis, Deals By Therapy Area, 2012 to YTD 2018
Washington University in St Louis, Medical Devices Deals, 2012 to YTD 2018
Washington University in St Louis, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018
Pfizer Enters into Agreement with Washington University in St. Louis
GenVec Enters into Agreement with Washington University in St. Louis
MaxCyte Enters into Agreement with Washington University in St Louis
Turing Pharma Enters into Partnership with Washington University
Johnson & Johnson Innovation Enters into Research Agreement with Washington University
GenVec Enters into Agreement with Washington University at St. Louis
Q BioMed to Expand Option Agreement with Washington University
Disarm Therapeutics Enters into Licensing Agreement with Washington University in St. Louis
Canopy Biosciences Enters into Licensing Agreement with Washington University in St. Louis and Johns Hopkins University
Precision Virologics Enters into Licensing Agreement with Washington University
Accuronix Therapeutics Enters into Licensing Agreement with Washington University in St. Louis
ViewPoint Therapeutics Receives Technology Rights from University of Michigan and Washington University
Sage Therapeutics Enters Into Licensing Agreement With Washington University To Develop Gaba Receptor Small Molecules
ChromaDex Amends Licensing Agreement With Washington University For Nicotinamide Riboside
Fimbrion Therapeutics Enters into Licensing Agreement with Washington University
Washington University in St Louis, Key Competitors
Washington University in St Louis, Key Employees
Washington University in St Louis, Subsidiaries

LIST OF FIGURES

Washington University in St Louis, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Washington University in St Louis, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Washington University in St Louis, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Washington University in St Louis, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Washington University in St Louis, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Washington University in St Louis, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Washington University in St Louis, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Washington University in St Louis, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Washington University in St Louis, Medical Devices Deals, 2012 to YTD 2018 10
Skip to top


Ask Your Question

Washington University in St Louis - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: